» Articles » PMID: 37354814

Molecular Mechanisms of ROS-modulated Cancer Chemoresistance and Therapeutic Strategies

Overview
Date 2023 Jun 24
PMID 37354814
Authors
Affiliations
Soon will be listed here.
Abstract

Drug resistance is the main obstacle to achieving a cure in many cancer patients. Reactive oxygen species (ROS) are master regulators of cancer development that act through complex mechanisms. Remarkably, ROS levels and antioxidant content are typically higher in drug-resistant cancer cells than in non-resistant and normal cells, and have been shown to play a central role in modulating drug resistance. Therefore, determining the underlying functions of ROS in the modulation of drug resistance will contribute to develop therapies that sensitize cancer resistant cells by leveraging ROS modulation. In this review, we summarize the notable literature on the sources and regulation of ROS production and highlight the complex roles of ROS in cancer chemoresistance, encompassing transcription factor-mediated chemoresistance, maintenance of cancer stem cells, and their impact on the tumor microenvironment. We also discuss the potential of ROS-targeted therapies in overcoming tumor therapeutic resistance.

Citing Articles

Special Issue "Molecular Advances in Cancer and Cell Metabolism".

Mesuraca M, Quaresima B, Scicchitano S, Faniello M Int J Mol Sci. 2025; 26(5).

PMID: 40076503 PMC: 11899288. DOI: 10.3390/ijms26051876.


The Role of HK2 in Tumorigenesis and Development: Potential for Targeted Therapy with Natural Products.

He K, Tao F, Lu Y, Fang M, Huang H, Zhou Y Int J Med Sci. 2025; 22(4):790-805.

PMID: 39991762 PMC: 11843137. DOI: 10.7150/ijms.105553.


Role of Oxidative Stress in the Occurrence, Development, and Treatment of Breast Cancer.

Dong R, Wang J, Guan R, Sun J, Jin P, Shen J Antioxidants (Basel). 2025; 14(1).

PMID: 39857438 PMC: 11760893. DOI: 10.3390/antiox14010104.


Single-cell transcriptomics reveals over-activated reactive oxygen species pathway in hepatocytes in the development of hepatocellular carcinoma.

Wang X, Li P, Ji H, Xu Z, Xing H Sci Rep. 2024; 14(1):29809.

PMID: 39616235 PMC: 11608336. DOI: 10.1038/s41598-024-81481-0.


Leveraging the ROS-TME Axis for Cancer Treatment.

Papavassiliou K, Sofianidi A, Gogou V, Papavassiliou A Antioxidants (Basel). 2024; 13(11).

PMID: 39594507 PMC: 11591396. DOI: 10.3390/antiox13111365.